The Global Irritable Bowel Syndrome Treatment Market Is Witnessing High Growth Owing To the High Incidence of Irritable Bowel Syndrome among Individuals in the World

 

Irritable Bowel Syndrome Treatment 

Irritable Bowel Syndrome Treatment Market, by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and Others), by Medical Condition (IBS-constipation and IBS-diarrhea), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

Market Overview:

Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine (colon). It is a chronic condition that causes symptoms such as constipation, bloating, abdominal pain, diarrhea, and gas. The exact cause of IBS is not known, but it is believed to be a combination of factors such as abnormal intestinal contractions, nerve dysfunction, inflammation, and changes in gut bacteria. IBS is typically diagnosed based on symptoms, and there is no specific test to confirm the diagnosis. However, healthcare professionals may perform tests to rule out other conditions with similar symptoms. Treatment for IBS may involve lifestyle changes such as dietary modifications, stress management, and exercise, as well as medication to relieve symptoms.

Competitive Landscape:

Major players operating in the global Irritable Bowel Syndrome Treatment Market include Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., GSK plc., Novartis AG, Astellas Pharma Inc., Ardelyx, Bausch Health Companies Inc., Mallinckrodt, Synergy Pharma, and Abbott.

Key Market Drivers:

The rising prevalence of irritable bowel syndrome (IBS) among the population worldwide is the major driver of the global irritable bowel syndrome treatment market. For instance, according to the National Institutes of Health (NIH), around 11% of the global population is living with irritable bowel syndrome. Moreover, the growing geriatric population, changing lifestyles, and increasing awareness about the disease are the other factors contributing to market growth. The increase in research and development activities by pharmaceutical companies to develop more effective treatment options for IBS is also boosting the growth of the global irritable bowel syndrome treatment market.

Covid-19 Impact Analysis:

During the COVID-19 pandemic, there have been several developments in the global Irritable Bowel Syndrome Treatment Market. For instance, in June 2022, Ferring B.V. and I-MAB Biopharma Co., Ltd. partnered in order to develop advanced treatment options for inflammatory bowel disease (IBD), along with other inflammatory conditions.

Key Takeaways:

·       North America is expected to dominate the global irritable bowel syndrome treatment market due to the high prevalence of the disease in the region. The increasing awareness about the disease and the availability of advanced healthcare infrastructure are the other factors contributing to market growth in the region. For instance, in April 2022, Ardelyx introduced the first and only NHE3 inhibitor called IBSRELA for treating irritable bowel syndrome in adults.

·       The Asia Pacific region is expected to witness the highest growth rate due to the increasing population and rising prevalence of IBS in the region. Moreover, the high rate of developments by key companies in the region is estimated to enhance the growth of the global irritable bowel syndrome treatment market.  For instance, in March 2022, Indegene collaborated with metaMe Health, for introducing a prescription digital therapeutic called Regulora in the market, in order to treat abdominal pain resulting from Irritable Bowel Syndrome.